Volume 44, Number 10
Original Article
Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer
Breast cancer is the most common malignancy among Singaporean females, with approximately 1700 new cases and 400 deaths per year in the period between 2008 and 2012.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.
Original Article
Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting
Breast cancer is the leading female cancer in our multiethnic Singaporean population and the most frequent cause of cancer mortality in females. The age-standardised incidence rate of newly diagnosed breast cancers in females has increased almost 3-fold in the last 4 decades from 23.8 per 100,000 in 1975 to...
Original Article
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer
Globally, colorectal cancer (CRC) is the third most common cancer with 1 million new cases per year. In Singapore, CRC is the most common cancer (8206 new cases, 2006 to 2010), accounting for 18% and 14% of all cancers in males and females respectively. One in 25 male and...
Original Article
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma
Worldwide, pancreatic cancer is the thirteenth most common adult malignancy and the seventh most common cause of cancer death. In Singapore, it is the eleventh and twelfth most common cancer among Singaporean men and women respectively. Although pancreatic cancer did not feature among the 10 most common cancers in...
Original Article
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC)
Kidney cancer accounts for less than 1% of all cancers. There are over 200,000 new cases diagnosed with renal cell carcinoma (RCC) and over 100,000 deaths a year worldwide. It is slightly more common in men than in women, and is mainly detected in people in their middle age....